Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

Université Laval

$105,000.00

CRISPR-mediated engineering of autophagy-deficient human T lymphocytes for CAR-T cell immunotherapy

FY 2018-19

Summary
Fighting cancer is no easy task. Our immune system has the ability to detect and eradicate cancer cells, but these cells use a wide variety of mechanisms to evade or impair our immune surveillance. Hence restoring and strengthening our immune system is a promising approach to fight back diverse tumours. CAR-T cell immunotherapy, a promising treatment, consists of collecting patient's immune T cells and genetically reprogramming them to specifically target and destroy cancer cells. The engineered T cells are then administered to cancer patients to eradicate the malignant cells. This new treatment showed impressive results against blood cancers. However, treating solid tumours remains a difficult challenge for the scientific community and many hurdles need to be overcome before this therapy is accessible to all. During immune cells reprogramming, a new gene coding for a receptor called CAR (chimeric antigen receptor) is incorporated in the patient's immune cells. This CAR receptor will recognize cancer cells and trigger the immune response. Even if these CAR-T cells are effective against cancer cells in the bloodstream, they don't persist in solid tumours. This lack of activity is attributed to the low amount of nutrients and oxygen near the tumour, which activates a pathway called autophagy. Preliminary results showed that autophagy-deficient mice had a significantly enhanced anti-tumour activity against prostate and breast cancer cells. We hypothesize that autophagy-deficient CAR-T cells will have an increased lifespan and anti-tumour activity in solid tumours. This project aims at using a molecular scissor called CRISPR-Cas9 to simultaneously target and inactivate a gene essential for autophagy and insert the CAR receptor. By modifying the CAR specificity, it will be possible to generate CAR-T cells targeting a wide array of cancer. I will develop a safe, rapid and efficient method to generate powerful CAR-T cells against a variety of cancer cells.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
404093
Name
Levesque Sébastien
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
CRISPR-mediated engineering of autophagy-deficient human T lymphocytes for CAR-T cell immunotherapy
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Autophagy; Cancer Metabolism; Car-T Cells; Crispr-Cas9; Genetic Engineering; Immunotherapy; Solid Tumours
Abstract
Fighting cancer is no easy task. Our immune system has the ability to detect and eradicate cancer cells, but these cells use a wide variety of mechanisms to evade or impair our immune surveillance. Hence restoring and strengthening our immune system is a promising approach to fight back diverse tumours. CAR-T cell immunotherapy, a promising treatment, consists of collecting patient's immune T cells and genetically reprogramming them to specifically target and destroy cancer cells. The engineered T cells are then administered to cancer patients to eradicate the malignant cells. This new treatment showed impressive results against blood cancers. However, treating solid tumours remains a difficult challenge for the scientific community and many hurdles need to be overcome before this therapy is accessible to all. During immune cells reprogramming, a new gene coding for a receptor called CAR (chimeric antigen receptor) is incorporated in the patient's immune cells. This CAR receptor will recognize cancer cells and trigger the immune response. Even if these CAR-T cells are effective against cancer cells in the bloodstream, they don't persist in solid tumours. This lack of activity is attributed to the low amount of nutrients and oxygen near the tumour, which activates a pathway called autophagy. Preliminary results showed that autophagy-deficient mice had a significantly enhanced anti-tumour activity against prostate and breast cancer cells. We hypothesize that autophagy-deficient CAR-T cells will have an increased lifespan and anti-tumour activity in solid tumours. This project aims at using a molecular scissor called CRISPR-Cas9 to simultaneously target and inactivate a gene essential for autophagy and insert the CAR receptor. By modifying the CAR specificity, it will be possible to generate CAR-T cells targeting a wide array of cancer. I will develop a safe, rapid and efficient method to generate powerful CAR-T cells against a variety of cancer cells.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Levesque, Sébastien
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Université Laval - $105,000 Grant (2018-19) | Canada Spends